Market Overview

Ionis Pharmaceuticals to hold technology webcast


CARLSBAD, Calif., Dec. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Friday, December 13th at 11:00 a.m. Eastern Time to take a deep dive into antisense technology, Ionis' proprietary RNA-targeted drug discovery platform. The approximately two-hour webcast will include presentations from Ionis' key architects and pioneers of RNA-targeted therapeutics Stanley T. Crook, MD, PhD, chief executive officer and chairman; Brett P. Monia, PhD, chief operating officer; Frank C. Bennett, PhD, senior vice president, research and neurology, and Eric Swayze, PhD, vice president, chemistry. The agenda for the webcast will be as follows:

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)





Optimization of Antisense


Enhancing Productive Delivery in vivo (LICA)


New Routes of Local Delivery


Commercially Attractive Oral Delivery


Bridging the Gap Between the Gene and the Patient


New Advances in Core Antisense Research






Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to treat a broad range of diseases including cardiovascular diseases, neurological diseases, infectious diseases, pulmonary diseases and cancer.

To learn more about Ionis visit and follow us on twitter @ionispharma.

Cision View original content to download multimedia:

SOURCE Ionis Pharmaceuticals, Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at